XML 39 R28.htm IDEA: XBRL DOCUMENT v3.22.2
Collaboration and Other Agreements - I-Mab Biopharma (Details) - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended 9 Months Ended
Jun. 30, 2022
Mar. 31, 2022
Jun. 30, 2021
Jun. 30, 2022
Jun. 30, 2021
Sep. 30, 2020
Dec. 31, 2021
Dec. 31, 2020
Collaboration And Other Agreements [Line Items]                
Revenues $ 26,007   $ 30,757 $ 37,108 $ 47,638      
Deferred revenue, current 11,565     11,565     $ 20,646  
Deferred revenue, net of current portion 6,163     6,163     0  
I-Mab | I-Mab Biopharma Collaboration and License Agreement                
Collaboration And Other Agreements [Line Items]                
Non-refundable upfront payment           $ 15,000    
Potential development and regulatory milestone payments under agreement               $ 135,000
Development and regulatory milestones recognized   $ 5,000   5,000        
Estimated variable consideration           $ 1,000    
Revenues 600   $ 1,900 700 $ 2,500      
Deferred revenue 3,800     3,800     4,500  
One Time Millstone Credit             $ 4,500  
I-Mab | I-Mab Biopharma Collaboration and License Agreement | Maximum                
Collaboration And Other Agreements [Line Items]                
Potential proceeds from royalties (percent)           20.00%    
I-Mab | I-Mab Biopharma Collaboration And License Agreement Clinical Supply                
Collaboration And Other Agreements [Line Items]                
Revenues $ 300     $ 1,100